$1.90
arrow_drop_down4.04%Performance History
| Key Stats | |
|---|---|
| Open | $1.97 |
| Prev. Close | $1.98 |
| EPS | -3.13 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $56.29M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.90 | 1.98 |
| 52 Week Range | 1.25 | 32.41 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -3.13 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
About Aerovate Therapeutics (AVTE)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Timothy P. Noyes M.B.A.
- Headquarters
- Waltham
- Employees
- 43
- Exchange
- NASDAQ
Keep an eye on Aerovate Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Aerovate Therapeutics's (AVTE) price per share?
What is the 52-week high and low for Aerovate Therapeutics (AVTE)?
Is Aerovate Therapeutics (AVTE) a growth stock?
What is Aerovate Therapeutics (AVTE) stock price performance year to date (YTD)?
Is Aerovate Therapeutics (AVTE) a profitable company?
What is the market capitalization of Aerovate Therapeutics (AVTE)?
News
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference